1352754-37-0

Basic information

• Product Name: 3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-cyclopropylmethyl-6-(2-methyl-oxiranylmethyl)-[1,3]oxazinan-2-one
• Synonyms: 3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-cyclopropylmethyl-6-(2-methyl-oxiranylmethyl)-[1,3]oxazinan-2-one
• CAS NO: 1352754-37-0
• Molecular Weight: 408.335
• Mol File: 1352754-37-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-cyclopropylmethyl-6-(2-methyl-oxiranylmethyl)-[1,3]oxazinan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-cyclopropylmethyl-6-(2-methyl-oxiranylmethyl)-[1,3]oxazinan-2-one(1352754-37-0)
• EPA Substance Registry System: 3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-cyclopropylmethyl-6-(2-methyl-oxiranylmethyl)-[1,3]oxazinan-2-one(1352754-37-0)

Safety Data

• Hazardous Substances Data: 1352754-37-0(Hazardous Substances Data)

Upstream product

• 1352754-35-8 1-[(S)-1-(4-bromo-phenyl)-ethylamino]-3-cyclopropylmethyl-5-methyl-hex-5-en-3-ol 
• 1352754-34-7 4-[(S)-1-(4-bromo-phenyl)-ethylamino]-1-cyclopropyl-butan-2-one 
• 1352754-33-6 1-cyclopropyl-but-3-en-2-one 
• 1352754-36-9 3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-cyclopropylmethyl-6-(2-methyl-allyl)-[1,3]oxazinan-2-one 
• 5239-82-7 cyclopropylacetic acid 
• 227322-00-1 2-cyclopropyl-N-methoxy-N-methyl-acetamide 
• 27298-97-1 (S)-1-(4-bromophenyl)ethylamine 

Downstream Products

• 1352754-39-2 3-[(S)-1-(4-bromo-phenyl)-ethyl]-(S)-6-cyclopropylmethyl-6-(2-hydroxy-2-methyl-propyl)-[1,3]oxazinan-2-one 
• 1352754-38-1 (S)-6-cyclopropylmethyl-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethyl}-[1,3]oxazinan-2-one 
• 1352753-96-8 1-[5-(4-{(S)-1-[(S)-6-cyclopropylmethyl-6-(2-hydroxy-2-methyl-propyl)-2-oxo-[1,3]oxazinan-3-yl]-ethyl}-phenyl)-pyridin-2-yl]-cyclopropanecarboxylic acid amide 

Relevant articles and documents

SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE

The present invention relates to compounds defined by formula I: wherein the variables A1, A2, Cy1 Cy2, Cy3, E, R1a, R1b, R2, R3, n, and Q are as defined herein, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.